Top US Penny Stocks To Watch In December 2024

In This Article:

As December 2024 unfolds, the U.S. stock market is experiencing a notable upswing, with the S&P 500 and Nasdaq reaching record highs amid a post-election rally. For investors seeking opportunities outside of large-cap stocks, penny stocks—despite their somewhat outdated moniker—remain an intriguing area for potential growth. These smaller or newer companies often offer unique opportunities at lower price points, especially when they are backed by solid financial fundamentals and robust balance sheets.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

Inter & Co (NasdaqGS:INTR)

$4.46

$2B

★★★★☆☆

BAB (OTCPK:BABB)

$0.83

$5.94M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$145.16M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.99

$91.9M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.24

$8.91M

★★★★★★

RLX Technology (NYSE:RLX)

$1.88

$2.51B

★★★★★★

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.9381

$86.31M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.81

$401.48M

★★★★☆☆

Click here to see the full list of 709 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Compass Therapeutics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology and other diseases in the United States, with a market cap of approximately $228.40 million.

Operations: Currently, there are no reported revenue segments for this clinical-stage biopharmaceutical company.

Market Cap: $228.4M

Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company with a market cap of US$228.40 million, remains pre-revenue, reporting less than US$1 million in revenue. Despite being debt-free and having sufficient short-term assets to cover liabilities, the company has experienced shareholder dilution and is unprofitable with increasing losses over recent years. The management team is relatively new, which may impact strategic execution. Recent earnings reported a net loss of US$10.48 million for Q3 2024, consistent with previous periods. Although its cash runway appears stable for over two years under current conditions, profitability isn't anticipated soon.

NasdaqCM:CMPX Financial Position Analysis as at Dec 2024
NasdaqCM:CMPX Financial Position Analysis as at Dec 2024

Kaltura

Simply Wall St Financial Health Rating: ★★★★★☆